Sangamo Therapeutics (SGMOQ) Total Liabilities (2010 - 2025)

Sangamo Therapeutics' Total Liabilities history runs 16 years deep, the most recent figure standing at $74.0 million for Q4 2025.

• On a quarterly basis, Total Liabilities fell 6.15% year-over-year to $74.0 million in Q4 2025; TTM through Dec 2025 was $74.0 million, a 6.15% decrease from a year earlier, with the FY2025 full-year figure at $74.0 million, down 6.15% from the prior year.
• Total Liabilities declined to $74.0 million in Q4 2025 per SGMOQ's latest filing, from $82.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $407.7 million in Q1 2021 and bottomed at $69.3 million in Q2 2024.
• The 5-year median for Total Liabilities is $88.1 million (2023), against an average of $182.7 million.
• Across the five-year window, Total Liabilities surged 114.72% in 2021 and slumped 70.23% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $346.6 million in 2021, then fell by 22.8% to $267.6 million in 2022, then sank by 69.19% to $82.4 million in 2023, then declined by 4.33% to $78.9 million in 2024, then slipped by 6.15% to $74.0 million in 2025.
• Per Business Quant, the three latest SGMOQ Total Liabilities figures stand at $74.0 million (Q4 2025), $82.4 million (Q3 2025), and $78.0 million (Q2 2025).